Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2022

Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies

The role of KRAS inhibitor and other new treatment options in pancreatic cancer

Date

10 Sep 2022

Session

Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies

Topics

Tumour Site

Hepatobiliary Cancers;  Pancreatic Adenocarcinoma

Presenters

Eileen O'Reilly

Authors

E. O'Reilly

Author affiliations

  • New York, NY/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction and scientific background

Presenter: Angela Lamarca

Session: Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies

Resources:

Slides

Webcast

IDH1 and IDH2

Presenter: Maeve Lowery

Session: Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies

Resources:

Slides

Webcast

Discussion

Presenter: All Speakers

Session: Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.